Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00841828 | Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | completed | Phase 2 | 102 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT01036087 | Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer | completed | Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT01306942 | Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | completed | Phase 1 / Phase 2 | 37 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT01565499 | Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer | completed | Phase 2 | 83 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05298696 | Efficacy of Cilostazol in Prevention of Peripheral Neuropathy | completed | Phase 1 / Phase 2 | 71 | Mansoura UniversityOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT02894398 | Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant(INGE-B) | completed | Phase 2 | 388 | iOMEDICO AGINDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT05351021 | Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients | completed | Phase 2 | 76 | Mansoura UniversityOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT00128843 | Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients | completed | Phase 2 | 103 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT00128856 | Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients | completed | Phase 2 | 46 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT00129896 | Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients | completed | Phase 1 / Phase 2 | 73 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT04477616 | Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy | completed | Phase 2 | 160 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT02314156 | Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy | completed | Phase 2 | 67 | Northwestern UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02479997 | Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients | completed | Phase 2 | 130 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02401347 | Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors | completed | Phase 2 | 21 | Melinda TelliOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04320030 | [18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers(EITHICS) | completed | Phase 2 | 13 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT00608972 | Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer | completed | Phase 2 | 31 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02049957 | Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer | completed | Phase 2 | 118 | Calithera Biosciences, IncINDUSTRY | 3 | Feb 8, 2023 | clinicaltrials |
| NCT03732391 | Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA) | completed | Phase 2 | 22 | CORTESI LAURAOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03499899 | A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | completed | Phase 2 | 88 | Novartis PharmaceuticalsINDUSTRY | 17 | Jan 30, 2023 | clinicaltrials |
| NCT02236000 | A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 49 | NSABP Foundation IncNETWORK | 1 | Jan 26, 2023 | clinicaltrials |
| NCT01446016 | Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)(CAT) | completed | Phase 2 | 38 | The Methodist Hospital Research InstituteOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02652923 | Contrast Ultrasound Detection of Sentinel Lymph Nodes | completed | Phase 1 / Phase 2 | 98 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03430479 | Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 32 | Kyoto Breast Cancer Research NetworkOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT00773695 | A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer | completed | Phase 2 | 150 | Hoffmann-La RocheINDUSTRY | 1 | Jan 9, 2023 | clinicaltrials |
| NCT02438358 | Feasibility Study of Intraoperative Imaging in Breast Cancer | completed | Phase 1 / Phase 2 | 60 | Lumicell, Inc.INDUSTRY | 1 | Jan 5, 2023 | clinicaltrials |
| NCT02440230 | Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients(SEAT) | completed | Phase 2 | 110 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 30, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT02229136 | Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus | completed | Phase 2 | 104 | US Oncology ResearchINDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer(TOPACIO) | completed | Phase 1 / Phase 2 | 122 | Tesaro, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03735966 | Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients. | completed | Phase 2 | 75 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 1, 2022 | clinicaltrials |
| NCT01752907 | Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim(VINE) | completed | Phase 2 | 304 | AmgenINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT03344536 | A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05206656 | Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer | completed | Phase 2 | 80 | Hunan Cancer HospitalOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT00270413 | SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer | completed | Phase 2 | 19 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT00691678 | Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer | completed | Phase 2 | 53 | Dawn L. HershmanOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04871854 | Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints | completed | Phase 2 | 100 | Beni-Suef UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT04676516 | A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer(OTT-19-06) | completed | Phase 2 | 40 | Ottawa Hospital Research InstituteOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT02448771 | A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer | completed | Phase 1 / Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02910219 | Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients(HALT-D) | completed | Phase 2 | 53 | Sandra SwainOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT00530868 | Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer | completed | Phase 2 | 75 | University of Alabama at BirminghamOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT00930579 | Pre-Surgical Study: Effect of Metformin on Breast Cancer Proliferation | completed | Phase 2 | 35 | Columbia UniversityOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02730130 | Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients | completed | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT02285179 | Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen(Poseidon) | completed | Phase 1 / Phase 2 | 189 | The Netherlands Cancer InstituteOTHER | 4 | Oct 12, 2022 | clinicaltrials |
| NCT02806050 | Palbociclib and FES PET | completed | Phase 2 | 30 | University Medical Center GroningenOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03057600 | Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) | completed | Phase 2 | 52 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02370238 | A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer(FRIDA) | completed | Phase 2 | 194 | Dompé Farmaceutici S.p.AINDUSTRY | 7 | Sep 16, 2022 | clinicaltrials |
| NCT03167619 | Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)(DORA) | completed | Phase 2 | 45 | Duke UniversityOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03154749 | DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer | completed | Phase 2 | 93 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT03394027 | ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Mar 31, 2023source: clinicaltrials